In animal models of depression, naringenin treatment has been shown to upregulate BDNF, SHH, GLI1, NK2 Homeobox 2 (NKX2.2), and Paired box protein Pax-6 (PAX6). Here, NKX2-2 is linked to major depressive disorder.